Virax Biolabs fiscal 2026 annual report lands with $6.4 million cash, Fosun Diagnostics supply deal on the board

Virax Biolabs' fiscal 2026 annual report, filed July 2, 2026, shows cash of $6.4 million, total assets of $8.3 million, and shareholders' equity attributable to ordinary shareholders of $7.3 million. One week later, on July 9, the company announced a commercial supply agreement with Fosun Diagnostics to support commercial execution for ImmuneSelect. CEO James Foster addressed shareholders on both developments in a combined update.

The balance sheet print

The July 2 filing gives the market a clean read on where Virax Biolabs stands. Cash is $6.4 million. Total assets reach $8.3 million, with the gap between that number and the $7.3 million in shareholders' equity attributable to ordinary shareholders reflecting liabilities on the books. The source does not break those liabilities down further. The full annual report, now on file, is the document that carries the line-item detail.

The equity figure of $7.3 million is specific to ordinary shareholders. That attribution matters for anyone mapping the capital structure, though the shareholder update does not itemize other equity classes or obligations beyond what those three headline numbers imply.

Fosun Diagnostics and ImmuneSelect

Seven days after the balance sheet filing, the company disclosed the Fosun Diagnostics commercial supply agreement. The deal is described as supporting commercial execution for ImmuneSelect. Financial terms, volume commitments, and duration are absent from the shareholder update.

The back-to-back timing puts a reported cash position and a named commercial partner in front of investors at the same moment. How the Fosun Diagnostics relationship converts to revenue, and on what schedule, is the question the current disclosure does not answer.

What to watch

The next confirmable milestone is a follow-on filing or announcement that puts structure around the Fosun Diagnostics agreement: pricing, volume, or contract length. The fiscal 2026 annual report, filed July 2 and now on the record, contains the balance sheet detail the shareholder update only summarizes. Until more disclosure arrives, the $6.4 million cash figure and the named commercial partner are the two anchors on the tape.